- BD (BDX, Financial) unveils HemoSphere Alta™, an advanced hemodynamic monitoring platform with AI-driven algorithms.
- The platform introduces the Cerebral Autoregulation Index (CAI) and Acumen Hypotension Prediction Index (HPI) for improved critical care monitoring.
- Features include a 15" touchscreen, voice and gesture commands, enhancing workflow efficiency and user interface.
BD (Becton, Dickinson and Company) (BDX), a prominent player in the global medical technology arena, has announced the launch of the HemoSphere Alta™, its latest advanced hemodynamic monitoring platform. Incorporating cutting-edge AI-driven algorithms, this platform aims to assist clinicians in managing blood pressure instability and optimizing blood flow, which is crucial during high-stakes medical procedures.
The HemoSphere Alta™ platform introduces the pioneering Cerebral Autoregulation Index (CAI). This unique parameter provides insights into whether a patient's brain can maintain stable blood flow despite blood pressure fluctuations. The CAI utilizes the ForeSight IQ™ Sensor placed on the patient's forehead alongside the Acumen IQ™ Sensor connected to the arterial line, offering personalized blood pressure insights.
Another standout feature of the platform is the Acumen Hypotension Prediction Index (HPI) software. This component is essential in predicting potential low blood pressure events. It has been validated through numerous multicenter studies, demonstrating its effectiveness in reducing the depth, duration, and severity of hypotension.
The user interface is designed with efficiency in mind, featuring a larger 15" high-resolution touchscreen with customizable and split-screen displays. The platform also introduces voice and gesture command features, allowing for hands-free operation. These enhancements contribute to maintaining sterility in clinical settings and streamlining workflow, ultimately improving the user experience.
With the integration of AI and advanced algorithms, BD's HemoSphere Alta™ platform signifies a major advancement in critical care monitoring. It strengthens BD's position in providing smart, connected care technologies that leverage clinical data for improved decision support and patient outcomes. For more details about the HemoSphere Alta™, visit their website at bd.com/HemoSphereAlta.
